Acute myeloid leukemia
- Multiagent therapy in young adult AML (new combinations, trial AML1718 - NCT03455504)
- Treatments based on small molecule inhibitors and personalized therapy
- The impact of genetic lesions in predicting treatment resopnse
- Determination of disease persistance with genetic tests and single-cell studies
- The impact of mesurable reisdual disease assesment on treatment decision (RESOLVE, Horizon Europe grant N° 101136502)
- The impact of fitness on thearpy selection
- Thearpy of relase/refractory AML (IMPACT-AML https://impactaml.eu/, Horizon Europe grant N° 101104421)
- Functional studies to identify innovative targets and combinations
Acute lymphoblastic leukemia
- Treatment of patients with positive mesurable residual disease (trial ALL2418, NCT03610438)
- Molecular mechanisms underlying therapy resistance
- Functional studies to identify innovative targets and combinations
Myelodisplasia
- Therapies for patients afffected by myelodisplasia with escess of blasts
- Therapies that modify transcriptional profile
Blastic plasmocitoid dendritic cell neoplasms
- Clinical caracterization of patients
- Study of patients with BPDCN associated with other hematological malignancies
- Therapies based on anti-CD123 drugs
Clonal hematopoiesis
- Mechanisms of identification and characterization of affected patients
- Impact of clonal hematopoiesis in health and diseases
Other hematological malignancies
Researches on lymphomas, multiple myeloma, and other hematological malignancies may be defined with the support of a tutor selected within senior consultants in hematology unit of Ravenna.
